Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...

Since the start of this week\u0026#39;s trading, the EUR/USD pair has been attempting to rebound upwards, with gains reaching ...

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

美国当局认定诺和诺德减肥药已不再处于短缺，因销售平替版减肥药而爆红的远程医疗平台Hims & Hers也确定将停售仿制减肥药，引发股价崩跌22%，已从月初的高点腰斩。 Business Insider报道，Hims & Hers首席财务官Yemi ...

This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...

当地时间周五（2月21日），美国食品和药物管理局（FDA）官网显示，诺和诺德公司报告称司美格鲁肽注射液的短缺和停产情况已经解决。 FDA表格显示，用于治疗2型糖尿病的“Ozempic”（诺和泰）和用于体重管理的“Wegovy”（诺和盈）已经不再供不应求，这类热门药物的短缺情况最早始于2022年8月23日。 FDA称，诺和诺德现在可以在美国全国范围内满足患者的药物需求。这一决定意味着，复方药店将被禁 ...

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.

The report suggests compounders may be using illegally imported APIs made in unregistered overseas facilities.

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...